Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
The SURPASS study is enrolling patients at research sites across the U.S. and Europe
Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
Proceeds to support continued clinical advancement of lead program, VGA039, a first-in-class antibody targeting protein S for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)
AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress
ROC-101 exhibits favorable pharmacokinetics for once-daily dosing
AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in PAH and ILD-PH patients
Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna – the company’s first (and first for the field) registration intended trial will read in the first half of 2026
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna’s most advanced programs. We discuss Stiff Person Syndrome, myasthenia gravis, MS and more.
Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated with GBA Mutations
Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year
Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)
Capsida will also present data from its potential best-in-class programs for Parkinson’s disease associated with GBA mutations (CAP-003 PD-GBA) and Friedreich’s ataxia (CAP-004), as well as capsid engineering and manufacturing
Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson’s Disease Associated with GBA Mutations (PD-GBA)
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration support advancing CAP-003 into clinical development in 1H25.